申请人:GLAXO GROUP LIMITED
公开号:EP0344015A2
公开(公告)日:1989-11-29
The invention relates to tetracyclic ketones of the general formula (I)
wherein n represents 1, 2 or 3;
Im represents an imidazolyl group of the formula:
wherein one of the groups represented by R¹, R² and R³ is a hydrogen atom or a C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₆alkenyl, phenyl or phenylC₁₋₃alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C₁₋₆alkyl group;
Y represents a group -(CH₂)m_, where m represents 2, 3 or 4, or a group -X(CH₂)p-, where p represents 2 or 3, X represents an oxygen or a sulphur atom or a group NR⁴, where R⁴ is a C₁₋₆alkyl group, and X is attached to the benzene ring moiety of the molecule;
and physiologically acceptable salts and solvates thereof.
The compounds are potent and selective antagonists of the effect of 5-HT at 5-HT₃ receptors and are useful, for example, in the treatment of psychotic disorders, anxiety, and nausea and vomiting.
本发明涉及通式 (I) 的四环酮
其中 n 代表 1、2 或 3;
Im 代表式中的咪唑基团:
其中 R¹、R² 和 R³ 所代表的基团之一是氢原子或 C₁₋₆烷基、C₃₋₇环烷基、C₃₋₆烯基、苯基或苯基 C₁₋₃烷基,而另外两个基团(可以相同或不同)分别代表氢原子或 C₁₋₆烷基;
Y 代表基团-(CH₂)m_,其中 m 代表 2、3 或 4,或代表基团-X(CH₂)p-,其中 p 代表 2 或 3,X 代表氧原子或硫原子或基团 NR⁴,其中 R⁴ 是 C₁₋₆烷基,且 X 连接到分子的苯环分子上;
及其生理上可接受的盐和溶剂。
这些化合物是 5-HT₃ 受体上 5-HT 效应的强效选择性拮抗剂,可用于治疗精神障碍、焦虑、恶心和呕吐等疾病。